HC Wainwright reiterated their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a report released on Monday, Benzinga reports. The brokerage currently has a $5.00 target price on the stock.
Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 target price on shares of Prelude Therapeutics in a research note on Monday, September 16th.
Get Our Latest Analysis on Prelude Therapeutics
Prelude Therapeutics Stock Down 7.7 %
Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.46) earnings per share for the quarter, hitting the consensus estimate of ($0.46). On average, research analysts anticipate that Prelude Therapeutics will post -1.85 EPS for the current fiscal year.
Institutional Trading of Prelude Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Kennedy Capital Management LLC acquired a new stake in shares of Prelude Therapeutics during the first quarter valued at about $119,000. Exchange Traded Concepts LLC boosted its position in shares of Prelude Therapeutics by 32.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after purchasing an additional 15,682 shares during the period. Dimensional Fund Advisors LP increased its holdings in Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock valued at $111,000 after purchasing an additional 14,769 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Prelude Therapeutics by 2.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after purchasing an additional 14,226 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Prelude Therapeutics by 1.0% during the first quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock worth $4,821,000 after purchasing an additional 10,143 shares in the last quarter. 79.72% of the stock is currently owned by hedge funds and other institutional investors.
Prelude Therapeutics Company Profile
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
Recommended Stories
- Five stocks we like better than Prelude Therapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Stock Dividend Cuts Happen Are You Ready?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Top Biotech Stocks: Exploring Innovation Opportunities
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.